1 reports of this reaction
1.5% of all LYCOPODIUM CLAVATUM SPORE reports
#9 most reported adverse reaction
AGRAPHIA is the #9 most commonly reported adverse reaction for LYCOPODIUM CLAVATUM SPORE. There are 1 FDA adverse event reports linking LYCOPODIUM CLAVATUM SPORE to AGRAPHIA. This represents approximately 1.5% of all 65 adverse event reports for this drug.
Patients taking LYCOPODIUM CLAVATUM SPORE who experience agraphia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
AGRAPHIA is a less commonly reported adverse event for LYCOPODIUM CLAVATUM SPORE, but still significant enough to appear in the safety profile.
In addition to agraphia, the following adverse reactions have been reported for LYCOPODIUM CLAVATUM SPORE:
AGRAPHIA has been reported as an adverse event in 1 FDA reports for LYCOPODIUM CLAVATUM SPORE. This does not prove causation, but indicates an association observed in post-market surveillance data.
AGRAPHIA accounts for approximately 1.5% of all adverse event reports for LYCOPODIUM CLAVATUM SPORE, making it a notable side effect.
If you experience agraphia while taking LYCOPODIUM CLAVATUM SPORE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.